公开(公告)号：US11529344B2

公开(公告)日：2022-12-20

申请号：US16762388

申请日：2018-11-09

Applicant: Pfizer Inc.

Inventor： Manfred Kraus ,  Pei-Pei Kung ,  Thomas Andrew Paul ,  Shikhar Sharma ,  Dominique Verhelle

IPC: A61K31/4725 ,  A61P35/00 ,  A61K33/243 ,  A61K31/357 ,  A61K31/4412 ,  A61K31/4433 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/501 ,  A61K31/5355 ,  A61K39/395 ,  A61K45/06

Abstract: This invention relates to combination therapies comprising an EZH2 inhibitor and a chemotherapeutic agent, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses.

公开(公告)号：US10945994B2

公开(公告)日：2021-03-16

申请号：US15573190

申请日：2016-05-12

Applicant: Pfizer Inc. ,  iTeos Therapeutics

Inventor： Manfred Kraus ,  Sandra Cauwenberghs ,  Stefano Crosignani ,  Gregory Driessens

IPC: A61K31/404 ,  A61K39/395 ,  A61P35/00 ,  A61K45/06 ,  A61K31/519 ,  A61K31/53 ,  A61K31/495 ,  A61P31/12 ,  A61P15/00 ,  A61K31/337 ,  C07K16/28 ,  A61K9/00 ,  A61K39/00

Abstract: Combinations of an IDO1 inhibitor (e.g., a 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione compound), with an anti-PD1 antibody or anti-PD-L1 antibody, and an anti-4-1BB antibody, as selected anti-cancer or anti-viral agents are provided. Also provided are use of these combinations for the treatment and/or prevention of cancer and endometriosis.

公开(公告)号：US20200268740A1

公开(公告)日：2020-08-27

申请号：US16762388

申请日：2018-11-09

Applicant: Pfizer Inc.

Inventor： Manfred Kraus ,  Pei-Pei Kung ,  Thomas Andrew Paul ,  Shikhar Sharma ,  Dominique Verhelle

IPC: A61K31/4725 ,  A61K33/243 ,  A61K31/357 ,  A61K45/06 ,  A61P35/00 ,  A61K39/395 ,  A61K31/5355 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/501 ,  A61K31/4433 ,  A61K31/4412

Abstract: This invention relates to combination therapies comprising an EZH2 inhibitor and a chemotherapeutic agent, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses.

公开(公告)号：US20180125817A1

公开(公告)日：2018-05-10

申请号：US15573190

申请日：2016-05-12

Applicant: Pfizer Inc. ,  iTeos Therapeutics

Inventor： Manfred Kraus ,  Sandra Cauwenberghs ,  Stefano Crosignani ,  Gregory Driessens

IPC: A61K31/404 ,  A61K31/519 ,  A61K31/53 ,  A61K31/337 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28 ,  A61P15/00 ,  A61P31/12 ,  A61P35/00

CPC classification number: A61K31/404 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/337 ,  A61K31/495 ,  A61K31/519 ,  A61K31/53 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2300/00 ,  A61P15/00 ,  A61P31/12 ,  A61P35/00 ,  C07K16/2818

Abstract: Combinations of an IDO1 inhibitor (e.g., a 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione compound), with an anti-PD1 antibody or anti-PD-L1 antibody, and an anti-4-1BB antibody, as selected anti-cancer or anti-viral agents are provided. Also provided are use of these combinations for the treatment and/or prevention of cancer and endometriosis.